# Pacira Pharmaceuticals, Inc clinical trials: 102 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 102 trials with Pacira Pharmaceuticals, Inc as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pacira Pharmaceuticals, Inc: 102 rows for $5.10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pacira-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 102
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 102, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 18, 2025 | NCT06977568 | A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With... | Pacira Pharmaceuticals, Inc | Phase 2 | Terminated | Osteoarthritis of Hip | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06977568) |
| March 19, 2025 | NCT06884865 | A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Pacira Pharmaceuticals, Inc | Phase 2 | Recruiting | Osteoarthritis (OA) of the Knee | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06884865) |
| April 1, 2024 | NCT06340451 | Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity | Pacira Pharmaceuticals, Inc | Not applicable | Completed | Spasticity, Cerebral or Spinal Condition | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340451) |
| February 21, 2024 | NCT06271265 | Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | Pacira Pharmaceuticals, Inc | Phase 1 | Recruiting | Postoperative Pain | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06271265) |
| February 21, 2024 | NCT06269705 | ZILRETTA in Subjects With Shoulder Osteoarthritis | Pacira Pharmaceuticals, Inc | Phase 3 | Active not recruiting | Glenohumeral Osteoarthritis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06269705) |
| August 10, 2022 | NCT05495334 | Innovations in Genicular Outcomes Registry | Pacira Pharmaceuticals, Inc | Observational | Recruiting | Knee Osteoarthritis | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05495334) |
| July 13, 2022 | NCT05456490 | Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via... | Pacira Pharmaceuticals, Inc | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05456490) |
| December 15, 2021 | NCT05157841 | Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy | Pacira Pharmaceuticals, Inc | Phase 3 | Completed | Bunionectomy, Hallux Valgus | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05157841) |
| December 1, 2021 | NCT05139030 | Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty | Pacira Pharmaceuticals, Inc | Phase 3 | Completed | Knee Osteoarthritis, Pain Management | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05139030) |
| April 1, 2021 | NCT04826328 | Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy | Pacira Pharmaceuticals, Inc | Phase 1 | Completed | Pain, Postoperative, Bunion | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04826328) |
| August 19, 2020 | NCT04518462 | Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl... | Pacira Pharmaceuticals, Inc | Phase 3 | Completed | Lower Extremity Surgery, Bunion, Metatarsophalangeal Fushion, Midfoot Fusion, Hindfoot Fushion, Total Ankle Arthroplasty | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04518462) |
| March 3, 2020 | NCT04293809 | Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation | Pacira Pharmaceuticals, Inc | Phase 1 | Completed | Breast Augmentation | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04293809) |
| December 9, 2019 | NCT04191031 | Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty | Pacira Pharmaceuticals, Inc | Not applicable | Terminated | Post-Operative Pain Management | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04191031) |
| November 22, 2019 | NCT04173611 | Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy... | Pacira Pharmaceuticals, Inc | Phase 1 | Terminated | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04173611) |
| November 12, 2019 | NCT04160091 | Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis | Pacira Pharmaceuticals, Inc | Phase 2 | Terminated | Osteoarthritis of the Shoulder, Adhesive Capsulitis | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04160091) |
| October 8, 2019 | NCT04119687 | Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee | Pacira Pharmaceuticals, Inc | Phase 1 | Active not recruiting | Osteoarthritis, Knee | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04119687) |
| August 22, 2019 | NCT04065074 | Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip | Pacira Pharmaceuticals, Inc | Phase 2 | Completed | Osteoarthritis, Hip | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04065074) |
| June 28, 2019 | NCT04002089 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa)... | Pacira Pharmaceuticals, Inc | Phase 1 | Completed | Bunion | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04002089) |
| May 20, 2019 | NCT03955458 | EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture | Pacira Pharmaceuticals, Inc | Phase 4 | Withdrawn | Hip Fractures, Intertrochanteric Fractures | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03955458) |
| May 17, 2019 | NCT03954639 | Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL... | Pacira Pharmaceuticals, Inc | Phase 3 | Withdrawn | Bunion, Metatarsophalangeal Fusion, Midfoot Fusion, Hindfoot Fusion, Total Ankle Arthroplasty, Forefoot Surgery | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03954639) |
| April 25, 2019 | NCT03927911 | Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries | Pacira Pharmaceuticals, Inc | Phase 4 | Terminated | Postoperative Pain Management | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03927911) |
| April 10, 2019 | NCT03909516 | Evaluate the Iovera° Device in Treating Pain Associated With Anterior Cruciate Ligament Reconstruction | Pacira Pharmaceuticals, Inc | Not applicable | Withdrawn | ACL Reconstruction | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03909516) |
| February 26, 2019 | NCT03853694 | Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section | Pacira Pharmaceuticals, Inc | Phase 4 | Completed | Elective Cesarean Section, Pain Management | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03853694) |
| January 4, 2019 | NCT03793010 | Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis | Pacira Pharmaceuticals, Inc | Phase 3 | Terminated | Osteoarthritis, Hip | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03793010) |
| September 28, 2018 | NCT03688477 | Iovera° to Treat Pain Associated With ACL Reconstruction and Rehabilitation | Pacira Pharmaceuticals, Inc | Not applicable | Withdrawn | Anterior Cruciate Ligament Reconstruction | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03688477) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 2 |
| Phase 2 | 21 |
| Phase 2/3 | 4 |
| Phase 3 | 19 |
| Phase 4 | 23 |
| Not applicable | 13 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 74 |
| Terminated | 18 |
| Withdrawn | 4 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pain | 29 |
| Agnosia | 22 |
| Pain, Postoperative | 20 |
| Osteoarthritis | 19 |
| Osteoarthritis, Knee | 16 |
| Bunion | 5 |
| Osteoarthritis, Hip | 4 |
| Intestinal Obstruction | 4 |
| Hernia | 2 |
| Hallux Valgus | 2 |
| Hemorrhoids | 2 |
| Charcot-Marie-Tooth Disease | 1 |
| Nerve Compression Syndromes | 1 |
| Morton Neuroma | 1 |
| Meningeal Neoplasms | 1 |
| Meningitis | 1 |
| Hernia, Inguinal | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Diabetes Mellitus | 1 |
| Hip Fractures | 1 |
| Bursitis | 1 |
| Central Nervous System Neoplasms | 1 |
| Leukemia | 1 |
| Lymphoma | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Business management services in the United States](https://specstream.ai/data/businesses/business-management-services/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Aircraft service companies in the United States](https://specstream.ai/data/businesses/aircraft-service-companies/united-states)
- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
